0001209191-20-035949.txt : 20200611 0001209191-20-035949.hdr.sgml : 20200611 20200611163937 ACCESSION NUMBER: 0001209191-20-035949 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200609 FILED AS OF DATE: 20200611 DATE AS OF CHANGE: 20200611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kauffman Michael CENTRAL INDEX KEY: 0001364719 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 20957604 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 85 WELLS AVENUE, SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-09 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001364719 Kauffman Michael C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE NEWTON MA 02459 1 1 0 0 Chief Executive Officer Common Stock 2020-06-10 4 M 0 7500 4.752 A 562622 D Common Stock 2020-06-10 4 S 0 7500 18.1259 D 555122 D Common Stock 2020-06-09 4 M 0 7500 4.752 A 763989 I By Spouse Common Stock 2020-06-09 4 S 0 7500 18.4994 D 756489 I By Spouse Stock Option (right to buy) 4.752 2020-06-10 4 M 0 7500 0.00 D 2023-09-02 Common Stock 7500 341061 D Stock Option (right to buy) 4.752 2020-06-09 4 M 0 7500 0.00 D 2023-09-02 Common Stock 7500 385303 I By Spouse These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.01 to $18.23, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.17 to $18.83, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. /s/Christopher B. Primiano, Attorney-in-Fact for Michael Kauffman 2020-06-11